Cancer Nanotheranostics

After a quarter of century of express technological advances, research has publicized the convolution of cancer, a disease confidentially related to the dynamic transformation of the genome. It is here that Nanotechnology enters the fray offering a wealth of tools to diagnose and treat cancer. Nanotechnology offers numerous tools to diagnose and treat cancer, such as new imaging agents, multifunctional devices capable of overcome biological barriers to deliver therapeutic agents directly to cells and tissues involved in cancer growth and metastasis, and devices capable of predicting molecular changes to prevent action against precancerous cells. Nanomaterials-based delivery systems in Theranostics (Diagnostics & Therapy) provide better penetration of therapeutic and diagnostic substances within the body at a reduced risk in comparison to conventional therapies. At the present time, there is a growing need to enhance the capability of theranostics procedures where nanomaterials-based sensors may provide for the simultaneous detection of several gene-associated conditions and nanodevices with the ability to monitor real-time drug action. These innovative multifunctional nanocarriers for cancer theranostics may allow the development of diagnostics systems such as colorimetric and immunoassays, and in therapy approaches through gene therapy, drug delivery and tumor targeting systems in cancer. 
 

Cancer is one of the leading causes of death in the world and remains a difficult disease to treat. Current problems associated with conventional cancer chemotherapies include insolubility of drugs in aqueous medium; delivery of sub-therapeutic doses to target cells; lack of bioavailability; and most importantly, non-specific toxicity to normal tissues. Recent contributions of nanotechnology research address possible solutions to these conundrums. Nevertheless, challenges remain with respect to delivery to specific sites, real time tracking of the delivery system, and control over the release system after the drug has been transported to the target site.

Nanomedical research on nanoparticles is exploring these issues and has already been showing potential solutions for cancer diagnosis and treatment. But a heterogeneous disease like cancer requires smart approaches where therapeutic and diagnostic platforms are integrated into a theranostic approach. Theranostics – a combination of the words therapeutics and diagnostics – describes a treatment platform that combines a diagnostic test with targeted therapy based on the test results, i.e. a step towards personalized medicine. Making use of nanotechnology materials and applications, theranostic nanomedicine can be understood as an integrated nanotherapeutic system, which can diagnose, deliver targeted therapy and monitor the response to therapy.

Theranostic nanomedicine has the potential for simultaneous and real time monitoring of drug delivery, trafficking of drug and therapeutic responses.

 

 

 

  • Cancer Microenvironment
  • Stealth Nanoparticles and Tumour Penetrating Peptides
  • Photothermal and Photodynamic therapies
  • Ferrofluid and magnetic hyperthermia
  • New Nanomaterials
  • Imaging and Cancer Theranostics
  • Advances in Nanotechnology for cancer treatment
  • Translational Nanomedicines
  • Cancer Diagnostics

Related Conference of Cancer Nanotheranostics

October 21-22, 2019

23rd European Biotechnology Congress

Zurich, Switzerland
November 26-27, 2019

International Conference On Genomics and Molecular Biology

Lisbon | Portugal
November 26-27, 2019

International Conference on Cell and Gene Therapy

| Lisbon, Portugal
February 24-25, 2020

24th Global Congress on Biotechnology

London, UK
March 16-17, 2020 |

12th World Congress and Expo on Cell & Stem Cell Research

Chicago, Illinois, USA

Cancer Nanotheranostics Conference Speakers

Recommended Sessions

Related Journals

Are you interested in